Patents by Inventor Jingrong Jean Cui

Jingrong Jean Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic compounds and uses thereof
    Patent number: 11981684
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: May 14, 2024
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20240140964
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • MACROCYCLES AND THEIR USE
    Publication number: 20230257396
    Abstract: The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 17, 2023
    Inventor: Jingrong Jean CUI
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220324879
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: October 13, 2022
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20220112213
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: September 27, 2021
    Publication date: April 14, 2022
    Inventors: Jingrong Jean CUI, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11291667
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 5, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Dayong Zhai
  • Macrocyclic compounds and uses thereof
    Patent number: 11286264
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Macrocyclic compounds and uses thereof
    Patent number: 11155563
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 26, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20210214373
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • MACROCYCLIC KINASE INHIBITORS AND THEIR USE
    Publication number: 20210087206
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Evan W. ROGERS, Jane UNG, Han ZHANG, Jeffrey WHITTEN, Dayong ZHAI, Wei DENG, Jingrong Jean CUI
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20200216465
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: February 21, 2020
    Publication date: July 9, 2020
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Macrocycle kinase inhibitors
    Patent number: 10689400
    Abstract: The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 23, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Jane Ung
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20200157119
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: May 21, 2020
    Inventors: Jingrong Jean CUI, Evan W. ROGERS, Jane UNG, Jeffrey Whitten, Dayong Zhai, Wei DENG, Xin ZHANG, Zhongdong HUANG, Jing LIU, Han ZHANG
  • Diaryl macrocycles as modulators of protein kinases
    Patent number: 10618912
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
    Publication number: 20190381048
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 19, 2019
    Inventors: Jingrong Jean CUI, Dayong ZHAI
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20190169207
    Abstract: The present invention relates to certain diaryl inacrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 6, 2019
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • MACROCYCLE KINASE INHIBITORS
    Publication number: 20190169208
    Abstract: The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 6, 2019
    Inventors: Jingrong Jean CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI, Jane UNG
  • Diaryl macrocycles as modulators of protein kinases
    Patent number: 10246466
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 2, 2019
    Assignee: TP Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20170334929
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: May 31, 2017
    Publication date: November 23, 2017
    Inventors: Jingrong Jean CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI
  • Diaryl macrocycles as modulators of protein kinases
    Patent number: 9714258
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 25, 2017
    Assignee: TP Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai